Your session is about to expire
← Back to Search
DEXTENZA for Glaucoma (DEXTenSiVe Trial)
DEXTenSiVe Trial Summary
This trial is testing whether a higher dose of DEXTENZA is more effective than the standard care dexamethasone in patients undergoing trabeculectomy, trabeculectomy Ex-PRESS, Xen Gel stent, and Ahmed Valve surgery.
- Glaucoma Post-Surgery
DEXTenSiVe Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.DEXTenSiVe Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have an allergy to dexamethasone or prednisolone.You have taken part in another study with a new drug or device within the past month.You have been diagnosed with glaucoma and are currently undergoing certain types of glaucoma surgery such as trabeculectomy, trabeculectomy Ex-PRESS, Xen Gel stent, or Ahmed Valve surgery.
- Group 1: Topical Dexamethasone Treatment
- Group 2: DEXTENZA
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 60 Other Conditions - This treatment demonstrated efficacy for 60 other conditions.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent can DEXTENZA be considered harmful to individuals?
"A score of 3, the highest rating available, was given to DEXTENZA due to its status as a Phase 4 trial; this signifies that it has already been approved for use."
What prior experiments have been conducted relating to DEXTENZA?
"Currently, DEXTENZA is being evaluated in 553 active clinical trials with 144 of them reaching Phase 3. While the great majority are taking place around Mishawaka, Indiana, it has been studied at 18618 distinct locations worldwide."
What medical conditions typically require DEXTENZA treatment?
"DEXTENZA is primarily used to treat ophthalmia, sympathetic, however it has been known to be effective for other eye-related conditions like branch retinal vein occlusion and macular edema."
Is this research project still enrolling participants?
"At this juncture, the trial is not accepting any new patients. The research was initially posted on November 1st 2021 and edited for the last time of November 9th 2021. For those interested in other clinical trials, 355 studies related to inflammation are currently recruiting while 553 are searching for DEXTENZA participants."
What is the current enrolment figure for this research project?
"This experiment is no longer taking on new participants. The clinical trial was opened to enrollment in November 2021 and the listing was last updated that same month. If you are interested in other research, there are presently 355 studies recruiting patients with inflammation issues as well as 553 trials seeking volunteers for DEXTENZA testing."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger